These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 1612221)

  • 1. The link between hyperglycaemia and diabetic nephropathy.
    Larkins RG; Dunlop ME
    Diabetologia; 1992 Jun; 35(6):499-504. PubMed ID: 1612221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
    Stribling D; Armstrong FM; Harrison HE
    J Diabet Complications; 1989; 3(2):70-6. PubMed ID: 2526143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation.
    Keogh RJ; Dunlop ME; Larkins RG
    Metabolism; 1997 Jan; 46(1):41-7. PubMed ID: 9005967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular understanding of hyperglycemia's adverse effects for diabetic complications.
    Sheetz MJ; King GL
    JAMA; 2002 Nov; 288(20):2579-88. PubMed ID: 12444865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathogenesis and prevention of diabetic neuropathy and nephropathy.
    Greene D
    Metabolism; 1988 Feb; 37(2 Suppl 1):25-9. PubMed ID: 2828823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic mechanisms of diabetic nephropathy.
    Schena FP; Gesualdo L
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S30-3. PubMed ID: 15938030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephropathy in diabetes.
    Satirapoj B
    Adv Exp Med Biol; 2012; 771():107-22. PubMed ID: 23393675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic microvascular complications and growth factors.
    Pfeiffer A; Schatz H
    Exp Clin Endocrinol Diabetes; 1995; 103(1):7-14. PubMed ID: 7621107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms].
    Guillausseau PJ
    Diabete Metab; 1994; 20(2 Pt 2):219-28. PubMed ID: 8001709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.
    Chilelli NC; Burlina S; Lapolla A
    Nutr Metab Cardiovasc Dis; 2013 Oct; 23(10):913-9. PubMed ID: 23786818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norman MacAlister Gregg Lecture. The pathogenesis of diabetic retinopathy.
    Larkins RG; Dunlop ME; Johnson EI
    Aust N Z J Ophthalmol; 1996 May; 24(2):97-104. PubMed ID: 9199738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy.
    Sharma K; Ziyadeh FN
    Semin Nephrol; 1997 Mar; 17(2):80-92. PubMed ID: 9148380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
    Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
    J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy.
    Palm F
    Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):997-1001. PubMed ID: 17002679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
    Baba T; Neugebauer S; Watanabe T
    Drugs; 1997 Aug; 54(2):197-234. PubMed ID: 9257079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk factors for diabetic complications: Abnormality of polyol metabolism].
    Hotta N
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():60-6. PubMed ID: 12430208
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
    Hodgkinson AD; Søndergaard KL; Yang B; Cross DF; Millward BA; Demaine AG
    Kidney Int; 2001 Jul; 60(1):211-8. PubMed ID: 11422753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular understanding of adverse effects of hyperglycemia in diabetic nephropathy].
    Koya D
    Nihon Jinzo Gakkai Shi; 2007; 49(5):470-3. PubMed ID: 17695806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.